Drugs in Dev. Gastroenterology
Phase II
Sweden 
Lead Product(s) : Linaprazan Glurate
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Zentiva
Deal Size : $249.2 million
Deal Type : Licensing Agreement
Zentiva Inks €220M Deal for Former AstraZeneca GI Drug in Europe
Details : Under the licensing agreement, Zentiva will hold the rights for the commercialization and manufacturing of linaprazan glurate, in Europe.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $14.7 million
May 22, 2025
Lead Product(s) : Linaprazan Glurate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Zentiva
Deal Size : $249.2 million
Deal Type : Licensing Agreement
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
The Connection Study Continues After Pre-scheduled Data Monitoring Committee (DMC) Review
Details : IBP-9414 (lactobacillus Reuteri), strain-specific attributes which affect the NEC pathogenesis is world’s first approved probiotic drug with the goal to prevent life-threatening diseases in premature infants.
Product Name : IBP-9414
Product Type : Probiotic
Upfront Cash : Inapplicable
January 19, 2022
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – December 31, 2020
Details : IBT is currently developing IBP-9414 to prevent necrotizing enterocolitis, and to improve feeding tolerance in premature infants. IBP-9414 contains Lactobacillus reuteri as an active ingredient, which is a human bacterial strain found naturally in breast...
Product Name : IBP-9414
Product Type : Probiotic
Upfront Cash : Inapplicable
May 02, 2021
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IBT is developing the drug candidate IBP-9414, contains the active substance Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk, for the prevention of necrotizing enterocolitis and improvement of feeding tolerance i...
Product Name : IBP-9414
Product Type : Probiotic
Upfront Cash : Inapplicable
April 29, 2021
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Linaprazan Glurate
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Fourth Swedish National Pension Fund
Deal Size : $25.6 million
Deal Type : Financing
Details : The proceeds from the financing round will be used to perform a phase 2 clinical trial, which is expected to start in the second half of 2020.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 03, 2020
Lead Product(s) : Linaprazan Glurate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Fourth Swedish National Pension Fund
Deal Size : $25.6 million
Deal Type : Financing
Reset All
